Targeting angiopoietin-like protein 3 and interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db/db mice
Authors:
- 17 April 2026
- journal article
- Published by Springer Nature in Inflammation Research
- Vol. 75 (1)
Abstract
Concomitant liver and kidney injury is a critical pathological feature of metabolic disorders, but current organ-specific therapies often fail to provide cross-protection. Lipotoxicity is a core mechanism linking damage in both organs. Therefore, this study aimed to investigate whether simultaneously targeting ANGPTL3 and IL-1β could attenuate lipotoxicity and thereby ameliorate concomitant liver and kidney injury. A novel bispecific antibody (BsAb) targeting both ANGPTL3 and IL-1β was generated and characterized by SDS-PAGE, SEC-HPLC, thermal stability analysis, SPR and in vitro bioassay. Then, its protective effects were subsequently studied in the db/db mouse model and the underlying mechanisms were revealed by biochemical examinations, histopathological analysis, immunofluorescence (IF), ELISA, RNA-seq. Administration of the BsAb in db/db mice effectively improved liver and kidney function with alleviated liver steatosis and inflammation, as well as reduced kidney glomerular injury. Furthermore, the treatment attenuated lipotoxicity in both organs and ameliorated glycolipid metabolism disturbance including restored hepatic glycogen reserves and enhanced renal utilization of fatty acids. The results demonstrate that the anti-ANGPTL3/IL-1β BsAb alleviates concomitant liver and kidney injury in db/db mice by attenuating lipotoxicity and regulating glycolipid metabolism, which highlights a promising therapeutic approach for addressing multi-organ damage in metabolic disorders.Keywords
All Related Versions
Funding Information
- National Key Research and Development Program of China (2023YFC3404000)
- National Key Research and Development Program of China (2023YFC3503400)
- National Natural Science Foundation of China (82371781)
This publication has 52 references indexed in Scilit:
- ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectivesBiomedicine & Pharmacotherapy, 2025
- Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesityDiabetologia, 2024
- Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy miceInternational Immunopharmacology, 2023
- Crosstalk between the liver and kidney in diabetic nephropathyEuropean Journal of Pharmacology, 2022
- The cephalic phase of insulin release is modulated by IL-1βCell Metabolism, 2022
- Interpreting global trends in type 2 diabetes complications and mortalityDiabetologia, 2021
- VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responsesActa Pharmaceutica Sinica B, 2021
- Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1Cell, 2018
- Insulin Resistance, Obesity and Lipotoxicity2017
- ANGPTL3 is increased in both insulin-deficient and -resistant diabetic statesBiochemical and Biophysical Research Communications, 2004